| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1853.2 | 8.4 | 27.2 |
| Other income | 1.8 | 0.0 | 0.0 |
| Total income | 1855.0 | 8.4 | 27.2 |
| Profit before exceptional items & tax | 1761.0 | -68.0 | -60.7 |
| Exceptional items | 0.0 | -12.4 | 0.0 |
| Profit before tax | 1761.0 | -80.3 | -60.7 |
| Net profit | 1761.3 | -80.4 | -59.8 |
| Operating margin | 94.9% | -956.0% | -223.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +6713.20% |
|---|
NSE results filing, NSE: SPARC. Figures extracted from the filing.
Sun Pharma Advanced Research Company Ltd: key numbers
- Share price
- ₹196.73
- Market cap
- ₹6,384 Cr
- Revenue (annual)
- ₹1,879 Cr
- Net profit (annual)
- ₹1,553 Cr
- P/E (TTM)
- 4.0×Sector 47.4×
- Promoter holding
- 65.67%+0.00% QoQ
- FII holding
- 3.90%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharma Advanced Research Company Ltd
All →Sun Pharma Advanced Research Company Other Announcement
Sun Pharma Advanced Research Company Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026.
Sun Pharma Advanced Research Company Promoter Reclassification
Sun Pharma Advanced Research Company has submitted an application to stock exchanges to reclassify certain members from 'Promoter Group' to 'Public' category.
Sun Pharma Advanced Research Company Annual General Meeting
SPARC held its 21st Annual General Meeting on August 10, 2026, via video conferencing. The meeting covered routine business, including adoption of financial statements.
Sun Pharma Advanced Research Company Other Announcement
Sun Pharma Advanced Research Company Limited submitted the Monitoring Agency Report for the quarter ended June 30, 2026. The report confirms zero deviation in utilizing proceeds from its Rs. 599.98 Crore warrant issue.
- Value
- ₹600.0 Cr
Sun Pharma Advanced Research Company Q1 FY27 Results: Net Loss of ₹20.8 Cr, Loss Narrows
Sun Pharma Advanced Research Company Ltd reported revenue from operations of ₹39.9 Cr (+315.6% YoY) and a net loss of ₹20.8 Cr for Q1 FY27.
- Key figure
- Net loss ₹20.8 Cr
Sun Pharma Advanced Research Company Board Meeting Date
Sun Pharma Advanced Research Company Limited scheduled a Board Meeting for August 10, 2026. The meeting will consider unaudited financial results for the period ended June 2026.